Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Talon Therapeutics, Inc.ex99-1.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 7, 2013

Talon Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)
 
001-32626 32-0064979
 (Commission File Number) (IRS Employer
Identification No.)
 
400 Oyster Point Blvd., Suite 200
South San Francisco, CA 94080
(Address of principal executive offices and Zip Code)

(650) 588-6404
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 8.01.             Other Events.

On January 7, 2013, Talon Therapeutics, Inc. issued a press release stating that its Board of Directors has authorized a review of strategic alternatives and has engaged a financial advisor to provide advisory services. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01.             Financial Statements and Exhibits.

(d) Exhibits.

 Exhibit No.
 
Description
99.1
 
Talon Therapeutics, Inc. press release dated January 7, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  January 7, 2013 Talon Therapeutics, Inc.  
       
 
By:
/s/ Craig W. Carlson  
   
Craig W. Carlson
Sr. Vice President, Chief Financial Officer
 
 
 
 

 

INDEX TO EXHIBITS FILED WITH THIS REPORT

 Exhibit No.
 
Description
99.1
 
Talon Therapeutics, Inc. press release dated January 7, 2013.